Literature DB >> 7966509

A preliminary investigation of ibogaine: case reports and recommendations for further study.

S G Sheppard.   

Abstract

A naturally occurring substance, ibogaine, was taken by seven individuals who were addicted to opiates. Ibogaine, an alkaloid with psychotropic effects at doses of 200-300 mg and above, was taken in single doses of 700-1800 mg by the subjects in the study. At the end of the 24-38-hr psychoactive period induced by the drug at these doses, none of the subjects displayed significant opiate withdrawal symptoms. At the lowest dose of 700 mg, one subject recontinued his drug abuse after 2 days; of the remaining six individuals who took 1,000 mg or above, two relapsed after a number of weeks, one reverted to intermittent heroin use, and three appear to have remained drug-free 14 weeks or more after undergoing this experimental treatment. Ibogaine may be of value in the present and could serve as a model for the development of improved agents for the treatment of substance abuse in the future.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966509     DOI: 10.1016/0740-5472(94)90049-3

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  13 in total

Review 1.  Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy?

Authors:  Jeanine Ward; Christopher Rosenbaum; Christina Hernon; Christopher R McCurdy; Edward W Boyer
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity.

Authors:  E O'Hearn; M E Molliver
Journal:  J Neurosci       Date:  1997-11-15       Impact factor: 6.167

3.  Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.

Authors:  Sebastien Carnicella; Dao-Yao He; Quinn V Yowell; Stanley D Glick; Dorit Ron
Journal:  Addict Biol       Date:  2010-10       Impact factor: 4.280

4.  Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.

Authors:  Dao-Yao He; Nancy N H McGough; Ajay Ravindranathan; Jerome Jeanblanc; Marian L Logrip; Khanhky Phamluong; Patricia H Janak; Dorit Ron
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

Review 5.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

Review 6.  A review of transpersonal theory and its application to the practice of psychotherapy.

Authors:  M C Kasprow; B W Scotton
Journal:  J Psychother Pract Res       Date:  1999

7.  Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.

Authors:  Thomas Knuijver; Arnt Schellekens; Maarten Belgers; Rogier Donders; Toon van Oosteren; Kees Kramers; Robbert Verkes
Journal:  Addiction       Date:  2021-08-09       Impact factor: 7.256

Review 8.  Ibogaine and addiction in the animal model, a systematic review and meta-analysis.

Authors:  M Belgers; M Leenaars; J R Homberg; M Ritskes-Hoitinga; A F A Schellekens; C R Hooijmans
Journal:  Transl Psychiatry       Date:  2016-05-31       Impact factor: 6.222

Review 9.  The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Authors:  Rishab N Iyer; David Favela; Guoliang Zhang; David E Olson
Journal:  Nat Prod Rep       Date:  2021-03-04       Impact factor: 13.423

10.  Ligand induced conformational changes of the human serotonin transporter revealed by molecular dynamics simulations.

Authors:  Heidi Koldsø; Henriette Elisabeth Autzen; Julie Grouleff; Birgit Schiøtt
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.